IGLL5

Summary

IGLL5 (immunoglobulin lambda like polypeptide 5, HGNC:38476) is a protein-coding gene on chromosome 22q11.22, encoding Immunoglobulin lambda-like polypeptide 5 (B9A064).

This gene encodes one of the immunoglobulin lambda-like polypeptides. It is located within the immunoglobulin lambda locus but it does not require somatic rearrangement for expression. The first exon of this gene is unrelated to immunoglobulin variable genes; the second and third exons are the immunoglobulin lambda joining 1 and the immunoglobulin lambda constant 1 gene segments. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 100423062 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 5 total — 1 pathogenic, 2 likely-pathogenic
• Phenotypes (HPO): 2
• MANE Select transcript: NM_001178126

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:38476
Approved symbol	IGLL5
Name	immunoglobulin lambda like polypeptide 5
Location	22q11.22
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000254709
Ensembl biotype	protein_coding
Entrez	100423062

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000526893, ENST00000531372, ENST00000532223

RefSeq mRNA: 2 — MANE Select: NM_001178126 NM_001178126, NM_001256296

CCDS: CCDS54506

Canonical transcript exons

ENST00000526893 — 3 exons

Exon	Start	End
ENSE00002167426	22893700	22893818
ENSE00003661571	22895375	22896111
ENSE00003893621	22887816	22888259

Expression profiles

Bgee: expression breadth ubiquitous, 117 present calls, max score 99.28.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 5.4673 / max 1464.1072, expressed in 96 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
191257	8.6189	96
191274	5.4673	96
191230	0.5992	58
191275	0.2212	14

Top tissues by expression

126 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
duodenum	UBERON:0002114	99.28	gold quality
rectum	UBERON:0001052	98.74	gold quality
bone marrow cell	CL:0002092	98.54	gold quality
mucosa of transverse colon	UBERON:0004991	98.36	gold quality
lymph node	UBERON:0000029	98.14	gold quality
spleen	UBERON:0002106	98.07	gold quality
tonsil	UBERON:0002372	98.04	gold quality
vermiform appendix	UBERON:0001154	97.88	gold quality
bone marrow	UBERON:0002371	96.78	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	93.69	gold quality
saliva-secreting gland	UBERON:0001044	91.20	gold quality
small intestine Peyer’s patch	UBERON:0003454	90.50	gold quality
minor salivary gland	UBERON:0001830	90.46	gold quality
gall bladder	UBERON:0002110	90.38	gold quality
small intestine	UBERON:0002108	90.34	gold quality
transverse colon	UBERON:0001157	88.89	gold quality
colonic epithelium	UBERON:0000397	88.32	gold quality
blood	UBERON:0000178	85.25	gold quality
granulocyte	CL:0000094	85.11	gold quality
upper lobe of left lung	UBERON:0008952	83.93	gold quality
body of stomach	UBERON:0001161	83.83	gold quality
stomach	UBERON:0000945	81.29	gold quality
left uterine tube	UBERON:0001303	80.82	gold quality
fundus of stomach	UBERON:0001160	80.51	gold quality
lung	UBERON:0002048	79.69	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	78.52	silver quality
intestine	UBERON:0000160	78.27	gold quality
fallopian tube	UBERON:0003889	76.87	gold quality
right coronary artery	UBERON:0001625	76.55	gold quality
leukocyte	CL:0000738	76.54	gold quality

Single-cell (SCXA)

Detected in 24 experiment(s), a significant marker in 23.

Experiment	Marker?	Max mean expression
E-MTAB-8410	yes	100526.88
E-CURD-88	yes	87577.46
E-MTAB-9543	yes	46286.78
E-MTAB-6653	yes	44888.79
E-MTAB-6308	yes	38658.51
E-MTAB-9467	yes	38281.76
E-HCAD-9	yes	31692.58
E-HCAD-11	yes	30422.17
E-HCAD-4	yes	29458.27
E-MTAB-10553	yes	23287.89
E-MTAB-8495	yes	14347.21
E-MTAB-8207	yes	6402.87
E-CURD-112	yes	2439.85
E-MTAB-9067	yes	2166.48
E-CURD-46	yes	74.67

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): RUNX1

miRNA regulators (miRDB)

17 targeting IGLL5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6744-5P	99.93	66.82	748
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-762	99.58	66.61	1994
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-4498	99.47	67.42	2360
HSA-MIR-5001-5P	99.05	66.76	1972
HSA-MIR-3145-3P	98.85	69.07	2031
HSA-MIR-6755-3P	98.61	66.90	834
HSA-MIR-5572	98.55	65.84	970
HSA-MIR-193B-5P	97.91	65.88	837
HSA-MIR-6855-5P	97.51	66.03	830
HSA-MIR-410-5P	96.55	66.28	459
HSA-MIR-323B-5P	96.12	66.39	472
HSA-MIR-3170	95.84	64.32	721
HSA-MIR-494-5P	95.31	66.29	463
HSA-MIR-3679-5P	94.75	66.46	862
HSA-MIR-1185-5P	94.47	65.95	725

Literature-anchored findings (GeneRIF, showing 1)

• IGLL5 is correlated with tumor-infiltrating immune cells in clear cell renal cell carcinoma. (PMID:33449444)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
mus_musculus	Iglc2	ENSMUSG00000076937
mus_musculus	Iglc3	ENSMUSG00000105547
mus_musculus	Iglc1	ENSMUSG00000105906
mus_musculus	Iglc4	ENSMUSG00000106039
rattus_norvegicus	Iglc1	ENSRNOG00000058590
rattus_norvegicus		ENSRNOG00000077205
rattus_norvegicus		ENSRNOG00000079313
rattus_norvegicus		ENSRNOG00000086508

Paralogs (82): IGLL1 (ENSG00000128322), IGHV1OR15-9 (ENSG00000188403), IGKC (ENSG00000211592), IGLC1 (ENSG00000211675), IGLC2 (ENSG00000211677), IGLC3 (ENSG00000211679), IGLC7 (ENSG00000211685), TRDC (ENSG00000211829), IGHA2 (ENSG00000211890), IGHE (ENSG00000211891), IGHG4 (ENSG00000211892), IGHG2 (ENSG00000211893), IGHA1 (ENSG00000211895), IGHG1 (ENSG00000211896), IGHG3 (ENSG00000211897), IGHD (ENSG00000211898), IGHM (ENSG00000211899), IGHV6-1 (ENSG00000211933), IGHV1-2 (ENSG00000211934), IGHV1-3 (ENSG00000211935), IGHV2-5 (ENSG00000211937), IGHV3-7 (ENSG00000211938), IGHV3-11 (ENSG00000211941), IGHV3-13 (ENSG00000211942), IGHV3-15 (ENSG00000211943), IGHV3-16 (ENSG00000211944), IGHV1-18 (ENSG00000211945), IGHV3-20 (ENSG00000211946), IGHV3-21 (ENSG00000211947), IGHV3-23 (ENSG00000211949), IGHV1-24 (ENSG00000211950), IGHV2-26 (ENSG00000211951), IGHV4-28 (ENSG00000211952), IGHV3-33 (ENSG00000211955), IGHV4-34 (ENSG00000211956), IGHV3-35 (ENSG00000211957), IGHV3-38 (ENSG00000211958), IGHV4-39 (ENSG00000211959), IGHV1-45 (ENSG00000211961), IGHV1-46 (ENSG00000211962)

Protein

Protein identifiers

Immunoglobulin lambda-like polypeptide 5 — B9A064 (reviewed: B9A064)

Alternative names: G lambda-1, Germline immunoglobulin lambda 1

All UniProt accessions (2): A0A0B4J231, B9A064

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Secreted.

Tissue specificity. Contrary to IGLL1, not expressed in pre-B-cells.

Miscellaneous. Located within the immunoglobulin lambda locus, but does not require somatic rearrangement for expression.

Isoforms (2)

UniProt ID	Names	Canonical?
B9A064-1	1	yes
B9A064-2	2

RefSeq proteins (2): NP_001171597, NP_001243225 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003006	Ig/MHC_CS	Conserved_site
IPR003597	Ig_C1-set	Domain
IPR007110	Ig-like_dom	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR050160	MHC/Immunoglobulin	Family

Pfam: PF07654

UniProt features (8 total): region of interest 2, splice variant 2, signal peptide 1, chain 1, domain 1, disulfide bond 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
7T17	ELECTRON MICROSCOPY	5.26

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-B9A064-F1	75.15	0.51

Antibody-complex structures (SAbDab): 1 — 7T17

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (1): 136–195

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 51 (showing top): IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, GOBP_LEUKOCYTE_MEDIATED_IMMUNITY, GOBP_B_CELL_MEDIATED_IMMUNITY, GOBP_LYMPHOCYTE_MEDIATED_IMMUNITY, GOBP_ADAPTIVE_IMMUNE_RESPONSE, MORI_PRE_BI_LYMPHOCYTE_UP, GOBP_IMMUNE_EFFECTOR_PROCESS, RASHI_RESPONSE_TO_IONIZING_RADIATION_5, GOBP_ADAPTIVE_IMMUNE_RESPONSE_BASED_ON_SOMATIC_RECOMBINATION_OF_IMMUNE_RECEPTORS_BUILT_FROM_IMMUNOGLOBULIN_SUPERFAMILY_DOMAINS, GOCC_IMMUNOGLOBULIN_COMPLEX, YOSHIMURA_MAPK8_TARGETS_UP, MORI_IMMATURE_B_LYMPHOCYTE_DN, GOMF_ANTIGEN_BINDING, MORI_LARGE_PRE_BII_LYMPHOCYTE_UP, WANG_CISPLATIN_RESPONSE_AND_XPC_UP

GO Biological Process (1): immunoglobulin mediated immune response (GO:0016064)

GO Molecular Function (1): antigen binding (GO:0003823)

GO Cellular Component (3): extracellular exosome (GO:0070062), IgG immunoglobulin complex (GO:0071735), extracellular region (GO:0005576)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
B cell mediated immunity	1
binding	1
extracellular vesicle	1
immunoglobulin complex	1
cellular anatomical structure	1

Protein interactions and networks

STRING

2076 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IGLL5	IGHV4-38-2	P0DP08	999
IGLL5	CD79A	P11912	909
IGLL5	CD79B	P40259	857
IGLL5	MYC	P01106	795
IGLL5	VPREB1	P12018	776
IGLL5	IKZF1	Q13422	774
IGLL5	JCHAIN	P01591	699
IGLL5	TXNL1	O43396	678
IGLL5	GGT2P	P36268	656
IGLL5	OR2H2	O95918	647
IGLL5	RAG1	P15918	623
IGLL5	RAG2	P55895	622
IGLL5	OPN4	Q9UHM6	607
IGLL5	CD19	P15391	605
IGLL5	SUCO	Q9UBS9	605

IntAct

99 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
ALDH3A1	RCCD1	psi-mi:“MI:0914”(association)	0.640
IGLL5	IGLC7	psi-mi:“MI:0914”(association)	0.530
FRMD1	A2ML1	psi-mi:“MI:0914”(association)	0.530
TSPAN11	IGLL5	psi-mi:“MI:0914”(association)	0.530
CA8	IGLL5	psi-mi:“MI:0914”(association)	0.530
ULBP1	IGLL5	psi-mi:“MI:0914”(association)	0.530
DDX31	IGLL5	psi-mi:“MI:0914”(association)	0.530
ALDH3A1	IGLL5	psi-mi:“MI:0914”(association)	0.530
SSBP2	CLEC18A	psi-mi:“MI:0914”(association)	0.530
RIBC1	CNOT1	psi-mi:“MI:0914”(association)	0.530
CFTR	PLEKHG3	psi-mi:“MI:0914”(association)	0.480
TK1	IGLL5	psi-mi:“MI:0915”(physical association)	0.400
JUN		psi-mi:“MI:0914”(association)	0.350
ITGA9	IGLL5	psi-mi:“MI:0914”(association)	0.350
ASCC1	IGLL5	psi-mi:“MI:0914”(association)	0.350
SUSD3	IGLL5	psi-mi:“MI:0914”(association)	0.350
SNX27	IGLL5	psi-mi:“MI:0914”(association)	0.350

BioGRID (152): IGLL5 (Affinity Capture-MS), IGLL5 (Affinity Capture-MS), IGLL5 (Affinity Capture-MS), IGLC7 (Affinity Capture-MS), IGLL1 (Affinity Capture-MS), IGLL5 (Affinity Capture-MS), IGLL5 (Affinity Capture-MS), IGLL5 (Affinity Capture-MS), IGLL5 (Affinity Capture-MS), IGLL5 (Affinity Capture-MS), IGLL5 (Affinity Capture-MS), IGLC3 (Affinity Capture-MS), IGLC2 (Affinity Capture-MS), IGLC7 (Affinity Capture-MS), IGLL5 (Affinity Capture-MS)

ESM2 similar proteins: A4D1S0, A4K2S4, A6NMD0, B9A064, F8WCM5, H7C350, O00220, O14931, O15533, O70146, O73895, O75298, O76081, P01854, P01883, P14138, P15692, P15814, P16382, P20764, P24394, P49763, P61484, P83743, Q00731, Q0VCS0, Q15569, Q3UM83, Q5R8H1, Q5RFR2, Q5TJE4, Q63257, Q63572, Q68D85, Q6P050, Q6PZD2, Q6WG24, Q7TQM3, Q863Z5, Q8MJ02

Diamond homologs: A0A0A0MT76, B9A064, P15814, A0A5B9, A0M8Q6, P01838, P01839, P01843, P01844, P01845, P01846, P01847, P01850, P01851, P01852, P01863, P01865, P01870, P01871, P01875, P01877, P03988, P04221, P06333, P0CF74, P0CG04, P0DOX2, P0DOX8, P0DOY2, P0DOY3, P0DSE2, P0DTU4, P11272, P11364, P14427, P20756, P20760, P20764, P20766, P20767

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

5 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	2
Uncertain significance	1
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
638672	GRCh37/hg19 22q11.22-11.23(chr22:22971867-23643138)	Pathogenic
545273	NC_000022.11:g.(?22638171)(23320336_?)del	Likely pathogenic
565006	GRCh37/hg19 22q11.22-11.23(chr22:22997802-23650873)x1	Likely pathogenic

SpliceAI

319 predictions. Top by Δscore:

Variant	Effect	Δscore
22:22888257:CAGG:C	donor_loss	0.9800
22:22888260:GT:G	donor_loss	0.9800
22:22888261:T:A	donor_loss	0.9800
22:22895370:CACA:C	acceptor_loss	0.9800
22:22895372:CAG:C	acceptor_loss	0.9800
22:22895373:A:AC	acceptor_loss	0.9800
22:22895421:TG:T	acceptor_gain	0.9800
22:22895422:G:GC	acceptor_gain	0.9800
22:22888257:C:T	donor_gain	0.9700
22:22888255:GGCAG:G	donor_gain	0.9600
22:22888256:GCAGG:G	donor_gain	0.9600
22:22895373:A:AG	acceptor_gain	0.9600
22:22895374:G:GG	acceptor_gain	0.9600
22:22895419:TCTG:T	acceptor_gain	0.9600
22:22895374:GGTCA:G	acceptor_gain	0.9500
22:22895418:CTCTG:C	acceptor_gain	0.9500
22:22895420:CTG:C	acceptor_gain	0.9500
22:22895421:TGAGG:T	acceptor_gain	0.9500
22:22895371:A:AG	acceptor_gain	0.9400
22:22888256:GCAG:G	donor_gain	0.9300
22:22895374:GGTC:G	acceptor_gain	0.9300
22:22895370:C:G	acceptor_gain	0.9100
22:22888260:G:GG	donor_gain	0.9000
22:22895372:C:G	acceptor_gain	0.9000
22:22895411:C:CA	acceptor_gain	0.8600
22:22895374:GGT:G	acceptor_gain	0.8500
22:22895364:T:A	acceptor_gain	0.8200
22:22895527:G:GT	donor_gain	0.8200
22:22888223:G:GT	donor_gain	0.8100
22:22895369:A:AG	acceptor_gain	0.8100

AlphaMissense

1362 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
22:22895499:G:C	W150C	0.997
22:22895499:G:T	W150C	0.997
22:22895470:T:C	F141L	0.996
22:22895472:C:A	F141L	0.996
22:22895472:C:G	F141L	0.996
22:22895610:G:C	W187C	0.996
22:22895610:G:T	W187C	0.996
22:22895497:T:A	W150R	0.995
22:22895497:T:C	W150R	0.995
22:22895581:A:C	S178R	0.995
22:22895583:C:A	S178R	0.995
22:22895583:C:G	S178R	0.995
22:22895455:T:A	C136S	0.993
22:22895455:T:C	C136R	0.993
22:22895456:G:C	C136S	0.993
22:22895632:T:A	C195S	0.991
22:22895633:G:C	C195S	0.991
22:22895608:T:A	W187R	0.989
22:22895608:T:C	W187R	0.989
22:22895456:G:A	C136Y	0.988
22:22895459:T:C	L137P	0.988
22:22895633:G:A	C195Y	0.988
22:22895457:T:G	C136W	0.987
22:22895632:T:C	C195R	0.987
22:22895399:T:A	V117D	0.985
22:22895575:G:C	A176P	0.985
22:22895498:G:C	W150S	0.984
22:22895578:A:C	S177R	0.984
22:22895580:C:A	S177R	0.984
22:22895580:C:G	S177R	0.984

dbSNP variants (sampled 300 via entrez): RS1000284846 (22:22891718 CTTTG>C), RS1000491809 (22:22888175 C>A,G,T), RS1000506244 (22:22890807 T>C,G), RS1000842761 (22:22888050 G>A,T), RS1001171010 (22:22893181 C>A,T), RS1001228938 (22:22887229 A>C,G), RS1001448620 (22:22888491 C>A,G,T), RS1002132203 (22:22896272 G>A), RS1002546071 (22:22895182 T>C), RS1003791489 (22:22889330 G>A,C,T), RS1004182 (22:22893496 G>C), RS1004183 (22:22895015 G>A,C,T), RS1004732047 (22:22886788 A>G), RS1004743020 (22:22889878 G>T), RS1004793802 (22:22890160 C>G,T)

Disease associations

OMIM: gene `` | disease phenotypes: MIM:181500, MIM:207500, MIM:301800, MIM:614429

GenCC curated gene-disease

Mondo (3): schizophrenia (MONDO:0005090), imperforate anus (MONDO:0001046), ventricular septal defect (MONDO:0002070)

Orphanet (3): Non-syndromic anorectal malformation (Orphanet:557), NON RARE IN EUROPE: Schizophrenia (Orphanet:3140), NON RARE IN EUROPE: Ventricular septal defect (Orphanet:1480)

HPO phenotypes

2 total (2 of 2 shown, HPO-id order):

HPO	Term
HP:0100753	Schizophrenia
HP:0001629	Ventricular septal defect

GWAS associations

0 associations (top):

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D001006	Anus, Imperforate	C06.198.050; C16.131.314.094
D006345	Heart Septal Defects, Ventricular	C14.240.400.560.540; C14.280.400.560.540; C16.131.240.400.560.540

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

9 total (human), top 9 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects cotreatment, decreases methylation, decreases expression	2
tetrathiomolybdate	increases expression	1
perfluorooctanoic acid	decreases expression	1
Fulvestrant	decreases methylation, affects cotreatment	1
Microplastics	increases abundance, increases expression	1
Diuron	decreases expression	1
Polyethylene Terephthalates	increases abundance, increases expression	1
Tobacco Smoke Pollution	affects expression	1
Asbestos, Crocidolite	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	PHASE4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety